Most Read Articles
Roshini Claire Anthony, 2 days ago

Patients undergoing chemotherapy for breast or haematological cancers could potentially reduce their risk of chemotherapy-related cardiotoxicity with the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARBs), or beta-blockers as primary prevention, according to a systematic review and meta-analysis presented at the recent EuroEcho 2019 conference.

Tristan Manalac, 3 days ago
Users of electronic nicotine delivery systems are likely to have received a diagnosis of clinical depression in the past, according to a recent study.
Pearl Toh, 06 Dec 2019
Getting just under one extra hour of sleep per night can go a long way for the health of college students, who are often sleep-deprived, a study suggests.
Jairia Dela Cruz, Yesterday
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).

Adjuvant capecitabine extends survival >1 year longer vs observation for biliary tract cancer

Pearl Toh
08 Jun 2017

Treatment with capecitabine after surgery for biliary tract cancer improves overall survival (OS) by 15 months compared with observation after surgery, according to the BILCAP* study presented at the ASCO 2017 Annual Meeting in Chicago, Illinois, US.

“This study helps resolve long-standing questions about adjuvant treatment for biliary tract cancer, for which there has been no standard of care,” said ASCO Immediate Past President Dr Daniel Hayes of University of Michigan Comprehensive Cancer Center in Ann Arbor, Michigan, US.  

Median OS in the capecitabine arm was 51 months compared with 36 months in the observation arm─a more than 1-year extension in survival with capecitabine─in the intent-to-treat (ITT) population (p=0.097). [ASCO 2017, abstract 4006]  

In the per-protocol population, median OS was 53 months with capecitabine vs 36 months with observation, which translates to a 25 percent significant reduction in mortality risk (hazard ratio [HR], 0.75; p=0.028).

Sensitivity analyses also revealed statistically significant difference between the two groups, with the capecitabine-treated patients having a 29 percent reduced risk of death than those in the observation group (hazard ratio [HR], 0.71; p<0.01), after adjusting for gender, disease grade and nodal status.   

Commenting on the difference in statistical significance between the ITT and per-protocol analyses, lead author Dr John Neil Primrose of the University of Southampton, UK, said, “The ITT analysis escaped statistical significance, but it is clear from the survival curves there is sustained benefit in the experimental arm. As you know, the per-protocol analysis is clearly positive, and the sensitivity analysis … is strongly positive.”

The ITT population included patients who discontinued capecitabine early (before the full duration of 6 months was up), according to the researchers.

Adjuvant capecitabine also delayed the time to disease recurrence in the ITT population, with a median relapse-free survival of 25 months compared with 18 months for observation after surgery.

The multicentre, prospective, phase III study randomized 447 patients (median age, 63 years) with resected cholangiocarcinoma or gallbladder cancer with ECOG PS** ≤2 in 1:1 to oral capecitabine 1,250 mg/m2 twice daily from day 1–14, every 21 days for 8 cycles, or observation. They were followed up for at least 24 months, with >80 percent of the survivors were followed for ≥36 months.

Biliary tract cancer has been associated with a poor outcome, with only 20 percent of cases being suitable for surgical resection─of which fewer than 10 percent survive beyond 5 years.

“Capecitabine improves OS in biliary tract cancer when used as adjuvant and should become [the] standard of care,” said Primrose, adding that the survival benefit comes with minimal impact on quality of life.

Side effects with capecitabine were modest in the study, with rash on the hands and feet occurring most commonly, which the researchers said were not unexpected.

“I think oncologists will regard this as a definitive trial … a trial with a no treatment arm would not now be ethical or acceptable to patients,” said Primrose.  

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 2 days ago

Patients undergoing chemotherapy for breast or haematological cancers could potentially reduce their risk of chemotherapy-related cardiotoxicity with the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARBs), or beta-blockers as primary prevention, according to a systematic review and meta-analysis presented at the recent EuroEcho 2019 conference.

Tristan Manalac, 3 days ago
Users of electronic nicotine delivery systems are likely to have received a diagnosis of clinical depression in the past, according to a recent study.
Pearl Toh, 06 Dec 2019
Getting just under one extra hour of sleep per night can go a long way for the health of college students, who are often sleep-deprived, a study suggests.
Jairia Dela Cruz, Yesterday
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).